Hypothalamic gliosis is a cellular response that, in rodents, is necessary for weight gain and diet-induced obesity. Whether this inflammatory process in the mediobasal hypothalamus (MBH) plays a role in common obesity or change in weight status during growth and development in children is uncertain. Using T2-weighted MRI scans from a longitudinal population-based sample of young children, we measured signal ratios to evaluate evidence of MBH gliosis in relation to obesity and adiposity change over time. We included 169 children from 6 sites recruited as part of the NIH Adolescent Brain Cognitive Development (ABCD) study. Baseline T2-weighted MRI scans were analyzed for evidence of MBH gliosis based on the T2 intensity of the mean bilateral MBH/Amygdala signal ratio. Putamen/Amygdala was used as the control ratio. Models were adjusted for site, age, and sex. At baseline, mean age was 9.9 ± 0.6 y, 50% were female, and 64% were pre-pubertal. Mean BMI z-score was 0.77 ± 1.02 [23% with overweight (OV) and 21% with obesity (OB)]. At 1y assessments (10.8 mo. on average), mean ΔBMI z-score was 0.02 ± 0.36. MBH/Amygdala ratio was positively associated with BMI z-score (r=0.32, P<0.001) and waist/height ratio (r=0.26, P<0.001), a marker of metabolic risk, whereas the control ratio was not (r=-0.02, P=0.52 and r=-0.05, P=0.76). Overall, MBH/Amygdala ratio was not associated with ΔBMI z-score (r=-0.02, P=0.49), but a significant interaction [F(5,158)=5.16; P<0.001] indicated the relationship varied by group. Among children with OV, baseline MBH/Amygdala ratio positively correlated with ΔBMI z-score (r=0.43, P=0.01); this relationship was attenuated in children with OB (r=0.19, P=0.18) and absent among participants of normal weight (r=-0.07, P=0.36).

In conclusion, we found evidence that MBH gliosis is associated with excess adiposity in a large pediatric population. In children at risk for obesity, MBH gliosis may be an important predictor of increasing adiposity and metabolic risk.

Disclosure

L.E. Sewaybricker: None. S.J. Melhorn: None. E. Schur: None.

Funding

National Institutes of Health (R01DK117623, U01DA041022, U01DA041028, U01DA041048, U01DA041089, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U24DA041123, U24DA041147, U01DA041093, U01DA041025)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.